Targeting these immune blockades by using antibodies such as anti‐PD‐1 or anti‐PD‐L1 reactivated the effects of T cells on the tumour cells and achieved great successes in some patients with cancer including HCC.7, 8, 9. The gene discussed is PDCD1; the disease is cancer.